Decentralizing Syndromic PCR: The Point-of-Care Molecular Margin War
Dr. Dereck Mush, MD, MBA
What they do
Nanopath announced a $25 million Series B financing package on November 10, 2026, including $2 million in non-dilutive grants. Norwest and SV Health Investors' MedTech Convergence Fund co-led, with Labcorp Venture Fund participating. The financing supports manufacturing and initiation of an FDA 510(k) clinical study for a 15-minute vaginitis assay. The assay is under development and has not been FDA cleared or approved. Alison Burklund, PhD and Amogha Tadimety, PhD are co-founders and co-CEOs.
People in this update
The record
- Vertical
- Women's Health
- Sub-segment
- Point-of-care molecular testing
- Product type
- Diagnostics
- Stage
- Series B
- Headquarters
- Cambridge, Massachusetts, United States
- Region
- North America
- Founded
- 2020
- Total funding
- Undisclosed
Notable investors: Norwest, SV Health Investors MedTech Convergence Fund, Labcorp Venture Fund.
Also in Women's Health
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Curative Adjuvant Checkpoint Pivot: How Genentech's ATOMIC Approval Redefines Early GI Oncology Economics and Reflex Testing Infrastructure
Dr. Dereck Mush, MD, MBA
Liquid biopsy monitoring is turning precision oncology into a continuous process, not a one time test
Dr. Dereck Mush, MD, MBA
The Consumer-to-Clinical Bridge in Women's Health: Teal Health and the 2027 Coverage Rules
Dr. Dereck Mush, MD, MBA